LEVULAN (aminolevulinic acid hydrochloride) by PharmaIN is solution, photosensitization occurs through the metabolic conversion of aminolevulinic acid to protoporphyrin ix (ppix), a photosensitizer, which accumulates in the skin. First approved in 1999.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
LEVULAN is a topical aminolevulinic acid hydrochloride solution used in photodynamic therapy for actinic keratoses. The drug works by converting to protoporphyrin IX, a photosensitizer that accumulates in skin lesions and generates cytotoxic singlet oxygen when exposed to blue light illumination. Treatment requires combination use with the BLU-U Blue Light Photodynamic Therapy Illuminator.
Stable, mature product with modest Medicare utilization; small commercial team focused on dermatology market maintenance.
solution, photosensitization occurs through the metabolic conversion of aminolevulinic acid to protoporphyrin IX (PpIX), a photosensitizer, which accumulates in the skin. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
Worked on LEVULAN at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLEVULAN offers stable, niche dermatology commercial experience in a mature product with zero current job openings; career value lies in dermatology market expertise and device-drug combination experience. Professionals seeking growth acceleration or clinical development should consider this a consolidation role rather than a launch or growth opportunity.